Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-8,200
Closed -$2.29M 2198
2025
Q2
$2.29M Sell
8,200
-8,700
-51% -$2.46M ﹤0.01% 1360
2025
Q1
$5.27M Sell
16,900
-900
-5% -$266K 0.01% 1002
2024
Q4
$4.64M Sell
17,800
-6,200
-26% -$1.84M 0.01% 1044
2024
Q3
$7.73M Buy
24,000
+10,100
+73% +$3.3M 0.02% 851
2024
Q2
$4.34M Buy
13,900
+9,100
+190% +$2.67M 0.01% 1056
2024
Q1
$1.36M Buy
4,800
+2,500
+109% +$732K ﹤0.01% 1443
2023
Q4
$662K Buy
+2,300
New +$627K ﹤0.01% 1578

Other funds holding AMGN

Man Group's AMGN Position: Q1 2026 in Review

Man Group reduced its Amgen (AMGN) stake by 46% in Q1 2026, selling an estimated $43.8M and leaving 142,525 shares worth $50.1M. The position accounts for 0.09% of the portfolio, ranked #239.

Man Group first reported a position in AMGN in Q1 2018 and has held it in 30 quarters since. The position peaked at $244M in Q3 2018. 3,128 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Man Group held 142,525 shares of Amgen worth $50.1M as of Q1 2026.
  • Man Group sold 122,859 Amgen shares in Q1 2026, an estimated $43.8M.
  • Amgen made up 0.09% of Man Group's portfolio in Q1 2026, its #239 holding.
  • Man Group first reported a position in Amgen in Q1 2018 and has held it in 30 quarters since.
  • Man Group's Amgen position peaked at $244M in Q3 2018.
  • 3,128 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.